Literature DB >> 7039516

Screening for cystic fibrosis by died blood spot trypsin assay.

A F Heeley, M E Heeley, D N King, J A Kuzemko, M P Walsh.   

Abstract

Immunoreactive trypsin was measured in dried blood specimens from 14,000 infants. A second test was performed in 0 . 2% of the population in whom blood trypsin levels were greater than 80 ng/ml. Five infants with cystic fibrosis were then detected, with only one case of persistent hypertrypsinaemia in whom this diagnosis could not be established. No false-negative test results have yet been identified. Seventeen infants with cystic fibrosis were tested inthe first 2 weeks of life, only one of whom had a blood trypsin concentration less than 80 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7039516      PMCID: PMC2863277     

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  Sensitive trypsin assay for dried-blood specimens as a screening procedure for early detection of cystic fibrosis.

Authors:  D N King; A F Heeley; M P Walsh; J A Kuzemko
Journal:  Lancet       Date:  1979-12-08       Impact factor: 79.321

2.  Dried blood spot screening for cystic fibrosis.

Authors:  D A Applegarth; A G Davidson; L T Kirby; M Bridges; P Sorensen; L T Wong; D F Hardwick
Journal:  Lancet       Date:  1979-12-08       Impact factor: 79.321

3.  Two tier screen for cystic fibrosis.

Authors:  P Dandona; J M Littlewood; L Ramdial; R Evans
Journal:  Lancet       Date:  1981-02-14       Impact factor: 79.321

4.  Screening for cystic fibrosis by a stool trypsin method.

Authors:  D C Forrest; B Wilcken; G Turner
Journal:  Arch Dis Child       Date:  1981-02       Impact factor: 3.791

5.  Dried-blood spot screening for cystic fibrosis in the newborn.

Authors:  J R Crossley; R B Elliott; P A Smith
Journal:  Lancet       Date:  1979-03-03       Impact factor: 79.321

  5 in total
  17 in total

1.  With commentary.

Authors:  P D Phelan
Journal:  Arch Dis Child       Date:  1982-10       Impact factor: 3.791

Review 2.  Neonatal screening--should we or shouldn't we?

Authors:  P H Weller; J V West
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

3.  Variations in dried blood spot immunoreactive trypsin in relation to gestational age and during the first week of life.

Authors:  J P Bourguignon; G Deby-Dupont; A Reuter; J Senterre; A Gérard; P Franchimont
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

Review 4.  An overview of the management of cystic fibrosis.

Authors:  J M Littlewood
Journal:  J R Soc Med       Date:  1986       Impact factor: 5.344

Review 5.  Nutritional management of the infant with cystic fibrosis.

Authors:  M R Green; E Buchanan; L T Weaver
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

6.  Screening for cystic fibrosis.

Authors:  J A Dodge; H C Ryley
Journal:  Arch Dis Child       Date:  1982-10       Impact factor: 3.791

7.  Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.

Authors:  R G Gregg; B S Wilfond; P M Farrell; A Laxova; D Hassemer; E H Mischler
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

8.  Screening for cystic fibrosis: a four year regional experience.

Authors:  G Roberts; M Stanfield; A Black; A Redmond
Journal:  Arch Dis Child       Date:  1988-12       Impact factor: 3.791

9.  Neonatal screening for cystic fibrosis in Wales and the West Midlands: 1. Evaluation of immunoreactive trypsin test.

Authors:  H C Ryley; S M Deam; J Williams; M Alfaham; P H Weller; M C Goodchild; R A Carter; D Bradley; J A Dodge
Journal:  J Clin Pathol       Date:  1988-07       Impact factor: 3.411

10.  Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period.

Authors:  L T Weaver; M R Green; K Nicholson; J Mills; M E Heeley; J A Kuzemko; S Austin; G A Gregory; A E Dux; J A Davis
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.